Cannabinoid Based Drug Discovery And Development Market By Drug Development Stage, By Receptor Target (CB1 Receptor, CB2 Receptor), By End User (Pharmaceutical Companies, Research Institutes, Contract Research Organizations): Global Opportunity Analysis and Industry Forecast, 2025-2034
The cannabinoid based drug discovery and development market was valued at $1.3billion in 2024 and is estimated to reach $1.8billion by 2034, exhibiting a CAGR of 3.3% from 2025 to 2034. The major factors driving the growth of the cannabinoid based drug discovery and development market are increasing research on therapeutic applications, regulatory approvals and legalization, rising prevalence of chronic diseases. The increasing research on therapeutic applications of cannabinoids is a key driver for the growth of the cannabinoid based drug discovery and development market.The increasing research on therapeutic applications is a major factor driving the growth of the cannabinoid based drug discovery and development market. Over the past few years, there has been a significant rise in scientific studies exploring the potential of cannabinoids in treating a wide range of medical conditions.
Researchers are investigating their effects on neurological disorders, chronic pain, cancer-related symptoms, and mental health issues, among others. For instance, in 2022 Icahn School of Medicine at Mount Sinai started a randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).The objective of this study is to assess dronabinol's effect on markers of inflammation in patients with SCD compared to placebo and to determine the safety and tolerability of dronabinol use in adults with SCD compared to placebo. The growing evidence supporting the medicinal benefits of cannabinoids has led to more investment in clinical trials and drug development.
As regulatory environments become more supportive, especially in regions where cannabis laws are evolving, there is an increase in both public and private sector involvement in this cannabinoid research. This surge in research not only accelerates the discovery of new therapeutic uses for cannabinoids but also improves their acceptance as legitimate medical treatments. Apurano Pharmaceuticals GmbH has drug candidate Adezunap which is currently under phase 3 clinical trials for treatment of chronic back pain, painful diabetic peripheral neuropathy, central neuropathic pain and chronic post traumatic/ post-surgical neuropathic pain. As healthcare providers and researchers continue to explore the pharmacological benefits of cannabinoids, the market is expected to witness significant growth.
The increasing prevalence of chronic diseases, including neurological disorders, cancer, and chronic pain conditions, is a major factor driving the growth of the cannabinoid based drug discovery and development market. As traditional treatment options often fail to provide adequate relief or come with significant side effects, there is a growing demand for alternative therapies, particularly those derived from cannabinoids.
Cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) have demonstrated therapeutic potential in managing pain, inflammation, seizures, and chemotherapy-induced nausea, making them attractive candidates for drug development. According to article by World Health Organization, it is estimated that over 1.8 million (as of 2023) people have multiple sclerosis worldwide and around 50 million (as of 2024) people worldwide have epilepsy. The rising global burden of conditions such as multiple sclerosis, epilepsy, and arthritis has spurred research efforts aimed at formulating cannabinoid based pharmaceuticals with improved efficacy and safety profiles.
Partnerships and funding for research play a crucial role in driving the growth of the cannabinoid based drug discovery and development market. Pharmaceutical companies, biotech firms, and academic institutions are increasingly collaborating to advance research on cannabinoids' therapeutic potential for conditions such as chronic pain, neurological disorders, and cancer. These partnerships facilitate resource sharing, access to specialized expertise, and streamlined drug development processes. In February 2023, Zelira Therapeutics received $8.6 million in funding from Cantheon Capital LLC for the study of its cannabinoid drug for use in patients with autism spectrum disorder. With the funds from Cantheon Capital LLC, Zelira will conduct FDA phases 2 and 3 clinical trials of HOPE 1 via a special purpose vehicle (SPV). This financial support allows for the exploration of innovative drug formulations and delivery systems, expanding the therapeutic indications for cannabinoid based drugs. Consequently, the combination of strategic collaborations and funding opportunities significantly fosters the growth and advancement of cannabinoid based drug discovery and development, positioning it as a promising segment within the broader pharmaceutical market.
The cannabinoid based drug discovery and development market is segmented on the basis of drug development stage, receptor target, end user, and region. On the basis of drug development stage, the market is divided into preclinical studies, and clinical trials. Depending on receptor target, the market is divided into CB1 (Agonist, Antagonist, and Inverse Agonist), CB2 (Agonist, Antagonist, and Inverse Agonist), FAAH Inhibitor, MAGL Inhibitor, FAAH-MAGL Dual Inhibitor, and TRPV1 (Agonist and Antagonist). On the basis of end user, the market is segmented into pharmaceutical companies, research institutes, and contract research organizations. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (India, South Korea, Australia, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Key Benefits for Stakeholders
By End User
Researchers are investigating their effects on neurological disorders, chronic pain, cancer-related symptoms, and mental health issues, among others. For instance, in 2022 Icahn School of Medicine at Mount Sinai started a randomized, double blind, study of dronabinol as a palliative agent in the treatment of pain, inflammation, and other complications of sickle cell disease (SCD).The objective of this study is to assess dronabinol's effect on markers of inflammation in patients with SCD compared to placebo and to determine the safety and tolerability of dronabinol use in adults with SCD compared to placebo. The growing evidence supporting the medicinal benefits of cannabinoids has led to more investment in clinical trials and drug development.
As regulatory environments become more supportive, especially in regions where cannabis laws are evolving, there is an increase in both public and private sector involvement in this cannabinoid research. This surge in research not only accelerates the discovery of new therapeutic uses for cannabinoids but also improves their acceptance as legitimate medical treatments. Apurano Pharmaceuticals GmbH has drug candidate Adezunap which is currently under phase 3 clinical trials for treatment of chronic back pain, painful diabetic peripheral neuropathy, central neuropathic pain and chronic post traumatic/ post-surgical neuropathic pain. As healthcare providers and researchers continue to explore the pharmacological benefits of cannabinoids, the market is expected to witness significant growth.
The increasing prevalence of chronic diseases, including neurological disorders, cancer, and chronic pain conditions, is a major factor driving the growth of the cannabinoid based drug discovery and development market. As traditional treatment options often fail to provide adequate relief or come with significant side effects, there is a growing demand for alternative therapies, particularly those derived from cannabinoids.
Cannabinoids such as cannabidiol (CBD) and tetrahydrocannabinol (THC) have demonstrated therapeutic potential in managing pain, inflammation, seizures, and chemotherapy-induced nausea, making them attractive candidates for drug development. According to article by World Health Organization, it is estimated that over 1.8 million (as of 2023) people have multiple sclerosis worldwide and around 50 million (as of 2024) people worldwide have epilepsy. The rising global burden of conditions such as multiple sclerosis, epilepsy, and arthritis has spurred research efforts aimed at formulating cannabinoid based pharmaceuticals with improved efficacy and safety profiles.
Partnerships and funding for research play a crucial role in driving the growth of the cannabinoid based drug discovery and development market. Pharmaceutical companies, biotech firms, and academic institutions are increasingly collaborating to advance research on cannabinoids' therapeutic potential for conditions such as chronic pain, neurological disorders, and cancer. These partnerships facilitate resource sharing, access to specialized expertise, and streamlined drug development processes. In February 2023, Zelira Therapeutics received $8.6 million in funding from Cantheon Capital LLC for the study of its cannabinoid drug for use in patients with autism spectrum disorder. With the funds from Cantheon Capital LLC, Zelira will conduct FDA phases 2 and 3 clinical trials of HOPE 1 via a special purpose vehicle (SPV). This financial support allows for the exploration of innovative drug formulations and delivery systems, expanding the therapeutic indications for cannabinoid based drugs. Consequently, the combination of strategic collaborations and funding opportunities significantly fosters the growth and advancement of cannabinoid based drug discovery and development, positioning it as a promising segment within the broader pharmaceutical market.
The cannabinoid based drug discovery and development market is segmented on the basis of drug development stage, receptor target, end user, and region. On the basis of drug development stage, the market is divided into preclinical studies, and clinical trials. Depending on receptor target, the market is divided into CB1 (Agonist, Antagonist, and Inverse Agonist), CB2 (Agonist, Antagonist, and Inverse Agonist), FAAH Inhibitor, MAGL Inhibitor, FAAH-MAGL Dual Inhibitor, and TRPV1 (Agonist and Antagonist). On the basis of end user, the market is segmented into pharmaceutical companies, research institutes, and contract research organizations. Region wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and Rest of Europe), Asia-Pacific (India, South Korea, Australia, and Rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and Rest of LAMEA).
Key Benefits for Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the cannabinoid based drug discovery and development market analysis from 2024 to 2034 to identify the prevailing cannabinoid based drug discovery and development market opportunities.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the cannabinoid based drug discovery and development market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global cannabinoid based drug discovery and development market trends, key players, market segments, application areas, and market growth strategies.
- Quarterly Update and* (only available with a corporate license, on listed price)
- 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
- Free Upcoming Version on the Purchase of Five and Enterprise User License.
- 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
- 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
- Free data Pack on the Five and Enterprise User License. (Excel version of the report)
- Free Updated report if the report is 6-12 months old or older.
- 24-hour priority response*
- Free Industry updates and white papers.
- Market share analysis of players by products/segments
- New Product Development/ Product Matrix of Key Players
- Additional company profiles with specific to client's interest
- Expanded list for Company Profiles
- Historic market data
By End User
- Pharmaceutical Companies
- Research Institutes
- Contract Research Organizations
- CB1 Receptor
- CB2 Receptor
- North America
- U.S.
- Canada
- Mexico
- Europe
- France
- Germany
- Italy
- Spain
- UK
- Rest of Europe
- Asia-Pacific
- India
- South Korea
- Australia
- Rest of Asia-Pacific
- LAMEA
- Brazil
- South Africa,
- Saudi Arabia
- Rest of LAMEA
- Key Market Players
- Jazz Pharmaceuticals, Inc (GW Pharmaceuticals)
- Corbus Pharmaceuticals Holdings
- Harmony Biosciences (Zynerba Pharmaceuticals)
- Pfizer (Arena Pharmaceuticals)
- InMed Pharmaceuticals
- Therapix Biosciences Ltd.
- Skye Bioscience, Inc (Emerald Health Pharmaceutical)
- CNBX
- Anebulo Pharmaceuticals
- Botanix Pharmaceuticals
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET
4.1. Overview
4.1.1. Market size and forecast
4.2. CB1 Receptor
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. CB2 Receptor
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical Companies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Research Institutes
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Contract Research Organizations
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Receptor Target
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Receptor Target
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Receptor Target
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Receptor Target
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Receptor Target
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. France
6.3.4.1.1. Market size and forecast, by Receptor Target
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. Germany
6.3.4.2.1. Market size and forecast, by Receptor Target
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. Italy
6.3.4.3.1. Market size and forecast, by Receptor Target
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Spain
6.3.4.4.1. Market size and forecast, by Receptor Target
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. UK
6.3.4.5.1. Market size and forecast, by Receptor Target
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Receptor Target
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Receptor Target
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. India
6.4.4.1.1. Market size and forecast, by Receptor Target
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. South Korea
6.4.4.2.1. Market size and forecast, by Receptor Target
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Receptor Target
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Rest of Asia-Pacific
6.4.4.4.1. Market size and forecast, by Receptor Target
6.4.4.4.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Receptor Target
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Receptor Target
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. South Africa,
6.5.4.2.1. Market size and forecast, by Receptor Target
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. Saudi Arabia
6.5.4.3.1. Market size and forecast, by Receptor Target
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Receptor Target
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2024
CHAPTER 8: COMPANY PROFILES
8.1. Jazz Pharmaceuticals, Inc (GW Pharmaceuticals)
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Corbus Pharmaceuticals Holdings
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Harmony Biosciences (Zynerba Pharmaceuticals)
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Pfizer (Arena Pharmaceuticals)
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. InMed Pharmaceuticals
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Therapix Biosciences Ltd.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Skye Bioscience, Inc (Emerald Health Pharmaceutical)
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. CNBX
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Anebulo Pharmaceuticals
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Botanix Pharmaceuticals
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter’s five forces analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.2. Restraints
3.4.3. Opportunities
CHAPTER 4: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET
4.1. Overview
4.1.1. Market size and forecast
4.2. CB1 Receptor
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. CB2 Receptor
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
CHAPTER 5: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER
5.1. Overview
5.1.1. Market size and forecast
5.2. Pharmaceutical Companies
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Research Institutes
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Contract Research Organizations
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION
6.1. Overview
6.1.1. Market size and forecast By Region
6.2. North America
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by Receptor Target
6.2.3. Market size and forecast, by End User
6.2.4. Market size and forecast, by country
6.2.4.1. U.S.
6.2.4.1.1. Market size and forecast, by Receptor Target
6.2.4.1.2. Market size and forecast, by End User
6.2.4.2. Canada
6.2.4.2.1. Market size and forecast, by Receptor Target
6.2.4.2.2. Market size and forecast, by End User
6.2.4.3. Mexico
6.2.4.3.1. Market size and forecast, by Receptor Target
6.2.4.3.2. Market size and forecast, by End User
6.3. Europe
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by Receptor Target
6.3.3. Market size and forecast, by End User
6.3.4. Market size and forecast, by country
6.3.4.1. France
6.3.4.1.1. Market size and forecast, by Receptor Target
6.3.4.1.2. Market size and forecast, by End User
6.3.4.2. Germany
6.3.4.2.1. Market size and forecast, by Receptor Target
6.3.4.2.2. Market size and forecast, by End User
6.3.4.3. Italy
6.3.4.3.1. Market size and forecast, by Receptor Target
6.3.4.3.2. Market size and forecast, by End User
6.3.4.4. Spain
6.3.4.4.1. Market size and forecast, by Receptor Target
6.3.4.4.2. Market size and forecast, by End User
6.3.4.5. UK
6.3.4.5.1. Market size and forecast, by Receptor Target
6.3.4.5.2. Market size and forecast, by End User
6.3.4.6. Rest of Europe
6.3.4.6.1. Market size and forecast, by Receptor Target
6.3.4.6.2. Market size and forecast, by End User
6.4. Asia-Pacific
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by Receptor Target
6.4.3. Market size and forecast, by End User
6.4.4. Market size and forecast, by country
6.4.4.1. India
6.4.4.1.1. Market size and forecast, by Receptor Target
6.4.4.1.2. Market size and forecast, by End User
6.4.4.2. South Korea
6.4.4.2.1. Market size and forecast, by Receptor Target
6.4.4.2.2. Market size and forecast, by End User
6.4.4.3. Australia
6.4.4.3.1. Market size and forecast, by Receptor Target
6.4.4.3.2. Market size and forecast, by End User
6.4.4.4. Rest of Asia-Pacific
6.4.4.4.1. Market size and forecast, by Receptor Target
6.4.4.4.2. Market size and forecast, by End User
6.5. LAMEA
6.5.1. Key market trends, growth factors and opportunities
6.5.2. Market size and forecast, by Receptor Target
6.5.3. Market size and forecast, by End User
6.5.4. Market size and forecast, by country
6.5.4.1. Brazil
6.5.4.1.1. Market size and forecast, by Receptor Target
6.5.4.1.2. Market size and forecast, by End User
6.5.4.2. South Africa,
6.5.4.2.1. Market size and forecast, by Receptor Target
6.5.4.2.2. Market size and forecast, by End User
6.5.4.3. Saudi Arabia
6.5.4.3.1. Market size and forecast, by Receptor Target
6.5.4.3.2. Market size and forecast, by End User
6.5.4.4. Rest of LAMEA
6.5.4.4.1. Market size and forecast, by Receptor Target
6.5.4.4.2. Market size and forecast, by End User
CHAPTER 7: COMPETITIVE LANDSCAPE
7.1. Introduction
7.2. Top winning strategies
7.3. Product mapping of top 10 player
7.4. Competitive dashboard
7.5. Competitive heatmap
7.6. Top player positioning, 2024
CHAPTER 8: COMPANY PROFILES
8.1. Jazz Pharmaceuticals, Inc (GW Pharmaceuticals)
8.1.1. Company overview
8.1.2. Key executives
8.1.3. Company snapshot
8.1.4. Operating business segments
8.1.5. Product portfolio
8.1.6. Business performance
8.1.7. Key strategic moves and developments
8.2. Corbus Pharmaceuticals Holdings
8.2.1. Company overview
8.2.2. Key executives
8.2.3. Company snapshot
8.2.4. Operating business segments
8.2.5. Product portfolio
8.2.6. Business performance
8.2.7. Key strategic moves and developments
8.3. Harmony Biosciences (Zynerba Pharmaceuticals)
8.3.1. Company overview
8.3.2. Key executives
8.3.3. Company snapshot
8.3.4. Operating business segments
8.3.5. Product portfolio
8.3.6. Business performance
8.3.7. Key strategic moves and developments
8.4. Pfizer (Arena Pharmaceuticals)
8.4.1. Company overview
8.4.2. Key executives
8.4.3. Company snapshot
8.4.4. Operating business segments
8.4.5. Product portfolio
8.4.6. Business performance
8.4.7. Key strategic moves and developments
8.5. InMed Pharmaceuticals
8.5.1. Company overview
8.5.2. Key executives
8.5.3. Company snapshot
8.5.4. Operating business segments
8.5.5. Product portfolio
8.5.6. Business performance
8.5.7. Key strategic moves and developments
8.6. Therapix Biosciences Ltd.
8.6.1. Company overview
8.6.2. Key executives
8.6.3. Company snapshot
8.6.4. Operating business segments
8.6.5. Product portfolio
8.6.6. Business performance
8.6.7. Key strategic moves and developments
8.7. Skye Bioscience, Inc (Emerald Health Pharmaceutical)
8.7.1. Company overview
8.7.2. Key executives
8.7.3. Company snapshot
8.7.4. Operating business segments
8.7.5. Product portfolio
8.7.6. Business performance
8.7.7. Key strategic moves and developments
8.8. CNBX
8.8.1. Company overview
8.8.2. Key executives
8.8.3. Company snapshot
8.8.4. Operating business segments
8.8.5. Product portfolio
8.8.6. Business performance
8.8.7. Key strategic moves and developments
8.9. Anebulo Pharmaceuticals
8.9.1. Company overview
8.9.2. Key executives
8.9.3. Company snapshot
8.9.4. Operating business segments
8.9.5. Product portfolio
8.9.6. Business performance
8.9.7. Key strategic moves and developments
8.10. Botanix Pharmaceuticals
8.10.1. Company overview
8.10.2. Key executives
8.10.3. Company snapshot
8.10.4. Operating business segments
8.10.5. Product portfolio
8.10.6. Business performance
8.10.7. Key strategic moves and developments
LIST OF TABLES
TABLE 01. GLOBAL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 02. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB1 RECEPTOR, BY REGION, 2024-2034 ($MILLION)
TABLE 03. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB2 RECEPTOR, BY REGION, 2024-2034 ($MILLION)
TABLE 04. GLOBAL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 05. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024-2034 ($MILLION)
TABLE 06. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR RESEARCH INSTITUTES, BY REGION, 2024-2034 ($MILLION)
TABLE 07. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2034 ($MILLION)
TABLE 08. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION, 2024-2034 ($MILLION)
TABLE 09. NORTH AMERICA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 10. NORTH AMERICA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 11. NORTH AMERICA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 12. U.S. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 13. U.S. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 14. CANADA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 15. CANADA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 16. MEXICO CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 17. MEXICO CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 18. EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 19. EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 20. EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 21. FRANCE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 22. FRANCE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 23. GERMANY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 24. GERMANY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 25. ITALY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 26. ITALY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 27. SPAIN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 28. SPAIN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 29. UK CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 30. UK CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 31. REST OF EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 32. REST OF EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 33. ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 34. ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 35. ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 36. INDIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 37. INDIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 38. SOUTH KOREA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 39. SOUTH KOREA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 40. AUSTRALIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 41. AUSTRALIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 43. REST OF ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 44. LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 45. LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 46. LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 47. BRAZIL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 48. BRAZIL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 49. SOUTH AFRICA, CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 50. SOUTH AFRICA, CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 51. SAUDI ARABIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 52. SAUDI ARABIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 53. REST OF LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 54. REST OF LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 55. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): KEY EXECUTIVES
TABLE 56. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 57. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): PRODUCT SEGMENTS
TABLE 58. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): SERVICE SEGMENTS
TABLE 59. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 60. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): KEY STRATERGIES
TABLE 61. CORBUS PHARMACEUTICALS HOLDINGS: KEY EXECUTIVES
TABLE 62. CORBUS PHARMACEUTICALS HOLDINGS: COMPANY SNAPSHOT
TABLE 63. CORBUS PHARMACEUTICALS HOLDINGS: PRODUCT SEGMENTS
TABLE 64. CORBUS PHARMACEUTICALS HOLDINGS: SERVICE SEGMENTS
TABLE 65. CORBUS PHARMACEUTICALS HOLDINGS: PRODUCT PORTFOLIO
TABLE 66. CORBUS PHARMACEUTICALS HOLDINGS: KEY STRATERGIES
TABLE 67. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): KEY EXECUTIVES
TABLE 68. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 69. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): PRODUCT SEGMENTS
TABLE 70. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): SERVICE SEGMENTS
TABLE 71. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 72. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): KEY STRATERGIES
TABLE 73. PFIZER (ARENA PHARMACEUTICALS): KEY EXECUTIVES
TABLE 74. PFIZER (ARENA PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 75. PFIZER (ARENA PHARMACEUTICALS): PRODUCT SEGMENTS
TABLE 76. PFIZER (ARENA PHARMACEUTICALS): SERVICE SEGMENTS
TABLE 77. PFIZER (ARENA PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 78. PFIZER (ARENA PHARMACEUTICALS): KEY STRATERGIES
TABLE 79. INMED PHARMACEUTICALS: KEY EXECUTIVES
TABLE 80. INMED PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 81. INMED PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 82. INMED PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 83. INMED PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 84. INMED PHARMACEUTICALS: KEY STRATERGIES
TABLE 85. THERAPIX BIOSCIENCES LTD.: KEY EXECUTIVES
TABLE 86. THERAPIX BIOSCIENCES LTD.: COMPANY SNAPSHOT
TABLE 87. THERAPIX BIOSCIENCES LTD.: PRODUCT SEGMENTS
TABLE 88. THERAPIX BIOSCIENCES LTD.: SERVICE SEGMENTS
TABLE 89. THERAPIX BIOSCIENCES LTD.: PRODUCT PORTFOLIO
TABLE 90. THERAPIX BIOSCIENCES LTD.: KEY STRATERGIES
TABLE 91. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): KEY EXECUTIVES
TABLE 92. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): COMPANY SNAPSHOT
TABLE 93. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): PRODUCT SEGMENTS
TABLE 94. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): SERVICE SEGMENTS
TABLE 95. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): PRODUCT PORTFOLIO
TABLE 96. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): KEY STRATERGIES
TABLE 97. CNBX: KEY EXECUTIVES
TABLE 98. CNBX: COMPANY SNAPSHOT
TABLE 99. CNBX: PRODUCT SEGMENTS
TABLE 100. CNBX: SERVICE SEGMENTS
TABLE 101. CNBX: PRODUCT PORTFOLIO
TABLE 102. CNBX: KEY STRATERGIES
TABLE 103. ANEBULO PHARMACEUTICALS: KEY EXECUTIVES
TABLE 104. ANEBULO PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 105. ANEBULO PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 106. ANEBULO PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 107. ANEBULO PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 108. ANEBULO PHARMACEUTICALS: KEY STRATERGIES
TABLE 109. BOTANIX PHARMACEUTICALS: KEY EXECUTIVES
TABLE 110. BOTANIX PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 111. BOTANIX PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 112. BOTANIX PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 113. BOTANIX PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 114. BOTANIX PHARMACEUTICALS: KEY STRATERGIES
TABLE 01. GLOBAL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 02. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB1 RECEPTOR, BY REGION, 2024-2034 ($MILLION)
TABLE 03. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB2 RECEPTOR, BY REGION, 2024-2034 ($MILLION)
TABLE 04. GLOBAL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 05. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR PHARMACEUTICAL COMPANIES, BY REGION, 2024-2034 ($MILLION)
TABLE 06. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR RESEARCH INSTITUTES, BY REGION, 2024-2034 ($MILLION)
TABLE 07. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2024-2034 ($MILLION)
TABLE 08. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY REGION, 2024-2034 ($MILLION)
TABLE 09. NORTH AMERICA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 10. NORTH AMERICA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 11. NORTH AMERICA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 12. U.S. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 13. U.S. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 14. CANADA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 15. CANADA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 16. MEXICO CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 17. MEXICO CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 18. EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 19. EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 20. EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 21. FRANCE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 22. FRANCE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 23. GERMANY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 24. GERMANY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 25. ITALY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 26. ITALY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 27. SPAIN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 28. SPAIN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 29. UK CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 30. UK CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 31. REST OF EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 32. REST OF EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 33. ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 34. ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 35. ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 36. INDIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 37. INDIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 38. SOUTH KOREA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 39. SOUTH KOREA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 40. AUSTRALIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 41. AUSTRALIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 42. REST OF ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 43. REST OF ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 44. LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 45. LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 46. LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY COUNTRY, 2024-2034 ($MILLION)
TABLE 47. BRAZIL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 48. BRAZIL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 49. SOUTH AFRICA, CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 50. SOUTH AFRICA, CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 51. SAUDI ARABIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 52. SAUDI ARABIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 53. REST OF LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024-2034 ($MILLION)
TABLE 54. REST OF LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024-2034 ($MILLION)
TABLE 55. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): KEY EXECUTIVES
TABLE 56. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 57. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): PRODUCT SEGMENTS
TABLE 58. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): SERVICE SEGMENTS
TABLE 59. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 60. JAZZ PHARMACEUTICALS, INC (GW PHARMACEUTICALS): KEY STRATERGIES
TABLE 61. CORBUS PHARMACEUTICALS HOLDINGS: KEY EXECUTIVES
TABLE 62. CORBUS PHARMACEUTICALS HOLDINGS: COMPANY SNAPSHOT
TABLE 63. CORBUS PHARMACEUTICALS HOLDINGS: PRODUCT SEGMENTS
TABLE 64. CORBUS PHARMACEUTICALS HOLDINGS: SERVICE SEGMENTS
TABLE 65. CORBUS PHARMACEUTICALS HOLDINGS: PRODUCT PORTFOLIO
TABLE 66. CORBUS PHARMACEUTICALS HOLDINGS: KEY STRATERGIES
TABLE 67. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): KEY EXECUTIVES
TABLE 68. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 69. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): PRODUCT SEGMENTS
TABLE 70. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): SERVICE SEGMENTS
TABLE 71. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 72. HARMONY BIOSCIENCES (ZYNERBA PHARMACEUTICALS): KEY STRATERGIES
TABLE 73. PFIZER (ARENA PHARMACEUTICALS): KEY EXECUTIVES
TABLE 74. PFIZER (ARENA PHARMACEUTICALS): COMPANY SNAPSHOT
TABLE 75. PFIZER (ARENA PHARMACEUTICALS): PRODUCT SEGMENTS
TABLE 76. PFIZER (ARENA PHARMACEUTICALS): SERVICE SEGMENTS
TABLE 77. PFIZER (ARENA PHARMACEUTICALS): PRODUCT PORTFOLIO
TABLE 78. PFIZER (ARENA PHARMACEUTICALS): KEY STRATERGIES
TABLE 79. INMED PHARMACEUTICALS: KEY EXECUTIVES
TABLE 80. INMED PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 81. INMED PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 82. INMED PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 83. INMED PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 84. INMED PHARMACEUTICALS: KEY STRATERGIES
TABLE 85. THERAPIX BIOSCIENCES LTD.: KEY EXECUTIVES
TABLE 86. THERAPIX BIOSCIENCES LTD.: COMPANY SNAPSHOT
TABLE 87. THERAPIX BIOSCIENCES LTD.: PRODUCT SEGMENTS
TABLE 88. THERAPIX BIOSCIENCES LTD.: SERVICE SEGMENTS
TABLE 89. THERAPIX BIOSCIENCES LTD.: PRODUCT PORTFOLIO
TABLE 90. THERAPIX BIOSCIENCES LTD.: KEY STRATERGIES
TABLE 91. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): KEY EXECUTIVES
TABLE 92. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): COMPANY SNAPSHOT
TABLE 93. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): PRODUCT SEGMENTS
TABLE 94. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): SERVICE SEGMENTS
TABLE 95. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): PRODUCT PORTFOLIO
TABLE 96. SKYE BIOSCIENCE, INC (EMERALD HEALTH PHARMACEUTICAL): KEY STRATERGIES
TABLE 97. CNBX: KEY EXECUTIVES
TABLE 98. CNBX: COMPANY SNAPSHOT
TABLE 99. CNBX: PRODUCT SEGMENTS
TABLE 100. CNBX: SERVICE SEGMENTS
TABLE 101. CNBX: PRODUCT PORTFOLIO
TABLE 102. CNBX: KEY STRATERGIES
TABLE 103. ANEBULO PHARMACEUTICALS: KEY EXECUTIVES
TABLE 104. ANEBULO PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 105. ANEBULO PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 106. ANEBULO PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 107. ANEBULO PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 108. ANEBULO PHARMACEUTICALS: KEY STRATERGIES
TABLE 109. BOTANIX PHARMACEUTICALS: KEY EXECUTIVES
TABLE 110. BOTANIX PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 111. BOTANIX PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 112. BOTANIX PHARMACEUTICALS: SERVICE SEGMENTS
TABLE 113. BOTANIX PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 114. BOTANIX PHARMACEUTICALS: KEY STRATERGIES
LIST OF FIGURES
FIGURE 01. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034
FIGURE 02. SEGMENTATION OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET,2024-2034
FIGURE 03. TOP IMPACTING FACTORS IN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET (2025-2034)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024 AND 2034(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB1 RECEPTOR, BY COUNTRY 2024 AND 2034(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB2 RECEPTOR, BY COUNTRY 2024 AND 2034(%)
FIGURE 14. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024 AND 2034(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY 2024 AND 2034(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR RESEARCH INSTITUTES, BY COUNTRY 2024 AND 2034(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2024 AND 2034(%)
FIGURE 18. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET BY REGION, 2024 AND 2034(%)
FIGURE 19. U.S. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 20. CANADA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 21. MEXICO CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 22. FRANCE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 23. GERMANY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 24. ITALY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 25. SPAIN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 26. UK CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 27. REST OF EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 28. INDIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 29. SOUTH KOREA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 30. AUSTRALIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 31. REST OF ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 32. BRAZIL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 33. SOUTH AFRICA, CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 34. SAUDI ARABIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 35. REST OF LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40. COMPETITIVE DASHBOARD
FIGURE 41. COMPETITIVE HEATMAP: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET
FIGURE 42. TOP PLAYER POSITIONING, 2024
FIGURE 01. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034
FIGURE 02. SEGMENTATION OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET,2024-2034
FIGURE 03. TOP IMPACTING FACTORS IN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET
FIGURE 04. TOP INVESTMENT POCKETS IN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET (2025-2034)
FIGURE 05. BARGAINING POWER OF SUPPLIERS
FIGURE 06. BARGAINING POWER OF BUYERS
FIGURE 07. THREAT OF SUBSTITUTION
FIGURE 08. THREAT OF SUBSTITUTION
FIGURE 09. COMPETITIVE RIVALRY
FIGURE 10. GLOBAL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
FIGURE 11. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY RECEPTOR TARGET, 2024 AND 2034(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB1 RECEPTOR, BY COUNTRY 2024 AND 2034(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CB2 RECEPTOR, BY COUNTRY 2024 AND 2034(%)
FIGURE 14. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, BY END USER, 2024 AND 2034(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR PHARMACEUTICAL COMPANIES, BY COUNTRY 2024 AND 2034(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR RESEARCH INSTITUTES, BY COUNTRY 2024 AND 2034(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY 2024 AND 2034(%)
FIGURE 18. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET BY REGION, 2024 AND 2034(%)
FIGURE 19. U.S. CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 20. CANADA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 21. MEXICO CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 22. FRANCE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 23. GERMANY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 24. ITALY CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 25. SPAIN CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 26. UK CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 27. REST OF EUROPE CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 28. INDIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 29. SOUTH KOREA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 30. AUSTRALIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 31. REST OF ASIA-PACIFIC CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 32. BRAZIL CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 33. SOUTH AFRICA, CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 34. SAUDI ARABIA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 35. REST OF LAMEA CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET, 2024-2034 ($MILLION)
FIGURE 36. TOP WINNING STRATEGIES, BY YEAR
FIGURE 37. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 38. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 39. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 40. COMPETITIVE DASHBOARD
FIGURE 41. COMPETITIVE HEATMAP: CANNABINOID BASED DRUG DISCOVERY AND DEVELOPMENT MARKET
FIGURE 42. TOP PLAYER POSITIONING, 2024
